<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145870</url>
  </required_header>
  <id_info>
    <org_study_id>PI2014_843_0009</org_study_id>
    <nct_id>NCT03145870</nct_id>
  </id_info>
  <brief_title>Prevalence of Asymptomatic Thrombosis in Multiple Myeloma</brief_title>
  <official_title>Prevalence of Asymptomatic Thrombosis in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant hemopathies, such as solid cancers, increase the risk of venous and arterial
      thromboembolic events. The incidence of symptomatic venous thromboembolic events is
      particularly high in myeloma, linked to the usual risk factors for venous thromboembolic
      disease, biological risk factors specific to myeloma, and especially to its treatments.

      The prevalence of asymptomatic venous thromboembolic events and arterial events are not known
      to date and remain important data for planning a possible randomized study to determine the
      most suitable thromboprophylaxis in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    investigator choice
  </why_stopped>
  <start_date type="Actual">June 3, 2014</start_date>
  <completion_date type="Actual">May 16, 2017</completion_date>
  <primary_completion_date type="Actual">May 16, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the occurrence of venous thromboembolic events via transverse Doppler echo</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thrombosis</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Patient with multiple symptomatic myeloma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echoing of the lower limbs and measuring the systolic pressure index</intervention_name>
    <description>Echoing of the lower limbs and measuring the systolic pressure index</description>
    <arm_group_label>Patient with multiple symptomatic myeloma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient major age â‰¥18 years

          -  Patients with symptomatic myeloma meeting the definition of the International Myeloma
             Working Group, regardless of the therapeutic line, including patients in remission and
             untreated.

          -  Patient having given informed consent, signed.

          -  Patient benefiting from a social security scheme

        Exclusion Criteria:

          -  Patients with non-symptomatic myeloma (stage I) or gammapathy of unknown significance
             (MGUS).

          -  Patient undergoing antithrombotic treatment for deep or superficial venous thrombosis
             and / or pulmonary embolism at the time of inclusion.

          -  Patients with occlusive arterial disease of the lower limbs known at the time of
             inclusion.

          -  Minors, protected adults and patients deprived of liberty or not affiliated to a
             social security scheme

          -  Pregnant woman

          -  Patient unable to express consent.

          -  Patient under guardianship or curatorship or patient deprived of public liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

